Sanara MedTech (NASDAQ:SMTI) Trading Down 1.6% – Time to Sell?

Sanara MedTech Inc. (NASDAQ:SMTI)’s share price traded down 1.6% during trading on Monday . The company traded as low as $21.56 and last traded at $22.09. 46,129 shares were traded during trading, a decline of 3% from the average session volume of 47,671 shares. The stock had previously closed at $22.44.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Sanara MedTech in a report on Tuesday, April 21st. Wall Street Zen upgraded Sanara MedTech from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Zacks Research downgraded Sanara MedTech from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 12th. Finally, Lake Street Capital initiated coverage on Sanara MedTech in a report on Wednesday, April 15th. They issued a “buy” rating and a $32.00 price objective for the company. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, Sanara MedTech has an average rating of “Hold” and an average price target of $34.00.

Sanara MedTech Stock Performance

The business has a fifty day simple moving average of $20.07 and a 200-day simple moving average of $20.93. The company has a quick ratio of 2.05, a current ratio of 2.28 and a debt-to-equity ratio of 6.59. The firm has a market cap of $210.59 million, a P/E ratio of -6.10 and a beta of 1.21.

Sanara MedTech (NASDAQ:SMTI) last posted its quarterly earnings data on Tuesday, March 24th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.07). The firm had revenue of $27.55 million during the quarter, compared to the consensus estimate of $27.90 million. Sanara MedTech had a negative return on equity of 3.19% and a negative net margin of 31.23%. On average, sell-side analysts predict that Sanara MedTech Inc. will post 0.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Sanara MedTech

Several institutional investors and hedge funds have recently modified their holdings of SMTI. BNP Paribas Financial Markets increased its holdings in shares of Sanara MedTech by 351.7% during the third quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock valued at $48,000 after acquiring an additional 1,171 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Sanara MedTech by 78.1% during the fourth quarter. Wells Fargo & Company MN now owns 3,322 shares of the company’s stock valued at $78,000 after acquiring an additional 1,457 shares in the last quarter. Lazard Asset Management LLC increased its holdings in shares of Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock valued at $89,000 after acquiring an additional 3,155 shares in the last quarter. Deutsche Bank AG increased its holdings in shares of Sanara MedTech by 171.1% during the fourth quarter. Deutsche Bank AG now owns 3,985 shares of the company’s stock valued at $93,000 after acquiring an additional 2,515 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Sanara MedTech by 44.1% during the third quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock valued at $101,000 after acquiring an additional 973 shares in the last quarter. 8.10% of the stock is currently owned by institutional investors.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.